Posted by Michael Wonder on 19 Jan 2021
Tessa Therapeutics receives PRIME designation from European Medicines Agency for CD30 CAR-T therapy
18 January 2021 - Tessa Therapeutics today announced that the EMA has granted PRiority MEdicines (PRIME) designation to the company's lead autologous CD30 CAR-T therapy for the treatment of relapsed or refractory classical Hodgkin's lymphoma.
The PRIME designation was granted by EMA on the back of promising clinical data from two Phase I/II trials in relapsed or refractory classical Hodgkin's lymphoma conducted at Baylor College of Medicine and University of North Carolina Lineberger Comprehensive Cancer Center.
